Pascal Soriot, Chief Executive Officer, commenting on the results, said:
"As anticipated, the first quarter performance reflects the loss of exclusivity for several large products. We remain focused on our strategic priorities of returning to growth and achieving scientific leadership. Brilinta, the diabetes franchise, Emerging Markets, Japan and our Respiratory products have all made good progress and we continued to invest in distinctive science that will advance our knowledge of disease physiology and help to identify new drug targets."
First quarter results 2013
Announced on Thursday 25 April 2013
Downloads
Analyst teleconference
12:00 (BST), 13:00 (CEST), 07:00 am (EDT)
| Location | Number | Conference ID |
|---|---|---|
| UK (freephone) | 0800 694 2370 | 33804527# |
| US (freephone) | 1 866 977 7645 | 33804527# |
| Sweden (freephone) | 0200 883 079 | 33804527# |
| International | +44 (0) 1452 557 749 | 33804527# |
Teleconference replay
A recording of the analyst conference will be available from 13:30 (BST) on Thursday 25 April until 13:30 (BST) Wednesday 8 May, on the following numbers:
| Location | Number | Conference ID |
|---|---|---|
| UK local | 0800 953 1533 | 33804527 |
| US (freephone) | 1 866 247 4222 | 33804527 |
| International | +44 (0) 1452 55 00 00 | 33804527 |